COVID-19 Vaccine Boosts immunotherapy Effectiveness in Lung Cancer & Melanoma, Study Finds
GAINESVILLE, FL – Patients with advanced lung cancer or melanoma who received COVID-19 mRNA vaccines prior to starting immunotherapy treatment lived significantly longer than those who did not, according to a new study from the University of Florida (UF Health). The research suggests the vaccines act as an “internal alarm,” priming the immune system to more effectively recognize and attack cancer cells, and enhancing the impact of immunotherapy.
The study, led by researchers Lin and Sayour, revealed that the mRNA vaccines trigger an immune response that causes tumors to produce more PD-L1 - a molecule that typically shields cancer cells from the body’s defenses. Immunotherapy drugs are specifically designed to block PD-L1, allowing immune cells to attack. The combination of the vaccine-induced immune activation and immunotherapy’s PD-L1 blockade creates a synergistic effect.
“the implications are unusual: it could revolutionize the entire field of cancer care,” said Dr. Elias Sayour, Ph.D., pediatric oncologist and co-senior author of the study.”We could design a non-specific vaccine that is even better at mobilizing and resetting the immune response, which could constitute a vaccine anticancer global and ready to use for all cancer patients.”
UF Health is preparing a multicenter, randomized phase III clinical trial to investigate integrating mRNA COVID-19 vaccination into the standard of care for patients beginning immunotherapy. If confirmed, the findings could repurpose mRNA vaccine technology – initially developed to combat viral infections – as a powerful new tool in cancer treatment.
